Topical Hydrogen Peroxide May Be Most Effective for Facial Seborrheic Keratoses
Dyspigmentation rates were lowest among seborrheic keratoses treated on the face.
Raised seborrheic keratoses (SKs) may clear better on the face than on the body following 40% hydrogen peroxide (HP40) therapy. Additionally, risk for dyspigmentation may also be lower on the face than on the body following HP40 application, according to study results published in the Journal of Drugs in Dermatology.
Researchers analyzed data pooled from 2 previous studies (ClinicalTrials.gov identifier: NCT02667236 and NCT02667275) that included 937 people with SKs. These participants were divided into the HP40 (n=467) group and the vehicle arm (n=470) group. Researchers used the Physician's Lesion Assessment scale to define clear and almost clear SKs following 2 treatments with HP40 applied 3 weeks apart. Delayed or immediate skin reactions were also recorded by location and categorized as delayed or immediate. To determine the mean-per-patient percent of SKs that were cleared or almost cleared by day 106, researchers conducted a sensitivity analysis.
The treatment response was superior with HP40 treatment compared with the vehicle arm in all SKs locations: 65% vs 10% on the face; 46% vs 5% on the trunk; and, 38% vs 9% on the extremities.
Facial SKs were more likely to be clear or almost clear following a single HP40 treatment at 43% compared with SKs on the trunk (31%) or on the extremities (14%).
The most common immediate reaction to HP40 application was erythema, stinging, and swelling, which resolved or improved within 1 week. Delayed reactions such as dyspigmentation and scarring were the least reported reactions in facial SKs.
Researchers concluded that “the recent FDA-approved 40% (w/w) hydrogen peroxide topical solution in a single-use applicator represents a novel SK treatment option for providers to offer to their patients.”
Disclosures: This study was supported by Aclaris Therapeutics, Inc. Stacy R. Smith, MD, has served on advisory boards for Aclaris Therapeutics. Shuai Xu, MD, is a consultant to Aclaris Therapeutics. Esther Estes, MD, and Stuart D. Shanler, MD, are employed by Aclaris Therapeutics.
Smith SR, Shuai X, Estes E, Shanler SD. Anatomic site-specific treatment response with 40% hydrogen peroxide (w/w) topical formulation for raised seborrheic keratoses: pooled analysis of data from two phase 3 studies. J Drugs Dermatol. 2018; 17(10):1092-1098.